SERPINA1
Basic information
Region (hg38): 14:94376747-94390693
Previous symbols: [ "PI" ]
Links
Phenotypes
GenCC
Source:
- alpha 1-antitrypsin deficiency (Limited), mode of inheritance: AR
- alpha 1-antitrypsin deficiency (Strong), mode of inheritance: AR
- alpha 1-antitrypsin deficiency (Strong), mode of inheritance: AR
- alpha 1-antitrypsin deficiency (Supportive), mode of inheritance: AR
- hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation (Supportive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Alpha-1-Antitrypsin deficiency | AR | Gastrointestinal; Pulmonary | Medical treatment (augmentation therapy with purified alpha-1-antitrypsin, Vitamin E supplementation) can be helpful for pulmonary and hepatic manifestations; Exacerbating factors (eg, smoking) should be avoided; Liver transplantation may be necessary in individuals with severe liver manifestations | Gastrointestinal; Pulmonary | 4240153; 4117022; 3494198; 2185272; 2035327; 7875269; 8066566; 10898319; 12740257; 11320399; 12452881; 12574076; 14522813; 15282394; 15214923; 20301692; 21457231; 21752289; 22016686; 22215832; 22330941; 22500781; 22536580; 22933512; 23055718; 23251618; 23766346 |
ClinVar
This is a list of variants' phenotypes submitted to
- Alpha-1-antitrypsin deficiency (17 variants)
- PI M(MALTON) (1 variants)
- PI S(IIYAMA) (1 variants)
- PI Q0(GRANITE FALLS) (1 variants)
- not provided (1 variants)
- SERPINA1-related disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SERPINA1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 130 | 136 | ||||
missense | 10 | 53 | 39 | 113 | ||
nonsense | 13 | |||||
start loss | 1 | |||||
frameshift | 17 | 26 | ||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 5 | |||||
splice region | 9 | 9 | ||||
non coding | 46 | 26 | 13 | 85 | ||
Total | 17 | 41 | 102 | 195 | 25 |
Highest pathogenic variant AF is 0.000177
Variants in SERPINA1
This is a list of pathogenic ClinVar variants found in the SERPINA1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
14-94376821-C-T | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 12, 2018) | ||
14-94376873-C-T | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 12, 2018) | ||
14-94376882-G-C | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94376894-G-A | Alpha-1-antitrypsin deficiency | Likely benign (Jan 12, 2018) | ||
14-94376955-T-A | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377035-C-T | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377118-C-T | PI KALSHEKER-POLLER • Alpha-1-antitrypsin deficiency | Benign/Likely benign (Jan 15, 2024) | ||
14-94377155-A-G | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377157-G-A | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377162-C-T | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377214-G-A | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377228-T-C | Alpha-1-antitrypsin deficiency | Benign (Jan 13, 2018) | ||
14-94377254-C-T | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 12, 2018) | ||
14-94377276-A-G | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377308-T-C | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377382-C-T | Alpha-1-antitrypsin deficiency | Benign (Jan 13, 2018) | ||
14-94377383-C-G | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 12, 2018) | ||
14-94377388-G-A | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377481-A-G | Alpha-1-antitrypsin deficiency | Benign (Jan 12, 2018) | ||
14-94377503-G-A | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377595-A-G | Alpha-1-antitrypsin deficiency | Benign (Jan 13, 2018) | ||
14-94377596-G-A | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377657-G-A | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) | ||
14-94377708-G-A | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 12, 2018) | ||
14-94377724-C-T | Alpha-1-antitrypsin deficiency | Uncertain significance (Jan 13, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SERPINA1 | protein_coding | protein_coding | ENST00000448921 | 4 | 13947 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
6.85e-8 | 0.150 | 125725 | 0 | 23 | 125748 | 0.0000915 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.373 | 242 | 226 | 1.07 | 0.0000121 | 2771 |
Missense in Polyphen | 54 | 58.882 | 0.91708 | 778 | ||
Synonymous | -0.0692 | 103 | 102 | 1.01 | 0.00000647 | 825 |
Loss of Function | 0.00374 | 11 | 11.0 | 0.999 | 4.78e-7 | 140 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000300 | 0.000300 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000968 | 0.0000967 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.000131 | 0.000131 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.;
- Disease
- DISEASE: Alpha-1-antitrypsin deficiency (A1ATD) [MIM:613490]: A disorder whose most common manifestation is emphysema, which becomes evident by the third to fourth decade. A less common manifestation of the deficiency is liver disease, which occurs in children and adults, and may result in cirrhosis and liver failure. Environmental factors, particularly cigarette smoking, greatly increase the risk of emphysema at an earlier age. {ECO:0000269|PubMed:1905728, ECO:0000269|PubMed:2227940, ECO:0000269|PubMed:2390072}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Complement and coagulation cascades - Homo sapiens (human);Nuclear Receptors Meta-Pathway;NRF2 pathway;Lung fibrosis;Dengue-2 Interactions with Complement and Coagulation Cascades;Complement and Coagulation Cascades;Neutrophil degranulation;Vesicle-mediated transport;Membrane Trafficking;Post-translational protein phosphorylation;Post-translational protein modification;Metabolism of proteins;Innate Immune System;Immune System;p73 transcription factor network;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);Platelet degranulation ;Response to elevated platelet cytosolic Ca2+;Platelet activation, signaling and aggregation;Cargo concentration in the ER;Transport to the Golgi and subsequent modification;Asparagine N-linked glycosylation;Hemostasis;FOXA1 transcription factor network;COPII-mediated vesicle transport;ER to Golgi Anterograde Transport
(Consensus)
Recessive Scores
- pRec
- 0.798
Intolerance Scores
- loftool
- 0.00462
- rvis_EVS
- 0.53
- rvis_percentile_EVS
- 81.01
Haploinsufficiency Scores
- pHI
- 0.195
- hipred
- N
- hipred_score
- 0.428
- ghis
- 0.850
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.975
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Serpina1e
- Phenotype
Gene ontology
- Biological process
- platelet degranulation;endoplasmic reticulum to Golgi vesicle-mediated transport;acute-phase response;blood coagulation;negative regulation of endopeptidase activity;neutrophil degranulation;post-translational protein modification;cellular protein metabolic process;COPII vesicle coating
- Cellular component
- Golgi membrane;extracellular region;extracellular space;endoplasmic reticulum;endoplasmic reticulum lumen;Golgi apparatus;COPII-coated ER to Golgi transport vesicle;platelet alpha granule lumen;endoplasmic reticulum-Golgi intermediate compartment membrane;intracellular membrane-bounded organelle;collagen-containing extracellular matrix;extracellular exosome;ficolin-1-rich granule lumen
- Molecular function
- protease binding;serine-type endopeptidase inhibitor activity;protein binding;identical protein binding